ClinicalTrials.gg
CompletedNCT01464190Updated Apr 1, 2014Results posted

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

A Phase 3 interventional study of PA21 (2.5 g tablet containing 500 mg iron) and Sevelamer carbonate in Chronic Kidney Disease Requiring Chronic Dialysis, sponsored by Vifor Pharma. Completed at 15 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-01.

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
659
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. This is an extension study to PA-CL-05A (NCT01324128), subjects have already been enrolled and have been treated with study medication for at least 24 weeks.

02

Conditions studied

  • Chronic Kidney Disease Requiring Chronic Dialysis

Keywords

  • PA21
  • Phosphate Binder
03

In context

Lead sponsor

Vifor Pharma is the lead sponsor of 22 studies on the registry; none are open to participants now.

First submitted before Vifor Pharma became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have completed treatment in Protocol PA-CL-05A
  • Written

Exclusion criteria

Exclusion Criteria:

  • Hyper/hypo calcemia; hyper intact parathyroid hormone (iPTH)
  • Other significant medical conditions
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
659 participants (actual)

Study arms

  • Experimental
    PA21

    Drug: PA21 (2.5 g tablet containing 500 mg iron)

  • Active comparator
    Sevelamer carbonate

    Drug: Sevelamer carbonate

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline and Levels at Each Time Point for Serum Phosphorus

    Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.

    Time frame: Every 4 weeks from baseline to Week 28

  2. Change From Baseline and Levels at Each Time Point for Serum Calcium

    Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.

    Time frame: Every 4 weeks from baseline to Week 28

  3. Change From Baseline and Levels at Each Time Point for Serum Intact Parathyroid Hormone (iPTH)

    Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.

    Time frame: Every 4 weeks from baseline to Week 28

07

Results

Posted Feb 17, 2014

Participant flow

Participant flow — Overall Study
MilestonePA21Sevelamer Carbonate
Started391268
Completed322227
Not completed6941

Outcome measures

PrimaryChange From Baseline and Levels at Each Time Point for Serum Phosphorus

Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.

Time frame:
Every 4 weeks from baseline to Week 28
Reported as:
Mean · mg/dL
Change From Baseline and Levels at Each Time Point for Serum Phosphorus
mg/dLPA21Sevelamer Carbonate
Change from Baseline to Week 4 (n = 346, 236)-0.2 ± 1.33-0.1 ± 1.47
Change from Baseline to Week 8 (n = 325, 238)-0.2 ± 1.380.1 ± 1.56
Change from Baseline to Week 12 (n = 322, 242)-0.0 ± 1.430.2 ± 1.55
Change from Baseline to Week 16 (n = 313, 228)0.0 ± 1.570.2 ± 1.75
Change from Baseline to Week 20 (n = 300, 221)-0.0 ± 1.460.1 ± 1.44
Change from Baseline to Week 24 (n = 286, 208)0.1 ± 1.530.2 ± 1.78
Chnage from Baseline to Week 28 (n = 287, 210)0.2 ± 1.520.2 ± 1.76
Change from Baseline to Endpoint (n = 384, 260)0.1 ± 1.620.3 ± 1.79
PrimaryChange From Baseline and Levels at Each Time Point for Serum Calcium

Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.

Time frame:
Every 4 weeks from baseline to Week 28
Reported as:
Mean · mg/dL
Change From Baseline and Levels at Each Time Point for Serum Calcium
mg/dLPA21Sevelamer Carbonate
Change from Baseline to Week 4 (n = 346, 236-1.2 ± 12.07-0.8 ± 13.37
Change from Baseline to Week 8 (n = 325, 238)-1.2 ± 12.301.5 ± 14.40
Change from Baseline to Week 12 (n = 321, 242)0.1 ± 12.941.9 ± 13.79
Change from Baseline to Week 16 (n = 313, 228)0.5 ± 14.042.0 ± 16.05
Change from Baseline to Week 20 (n = 300, 221)0.4 ± 13.241.6 ± 13.29
Change from Baseline to Week 24 (n = 284, 207)1.1 ± 13.572.2 ± 15.74
Change from Baseline to Week 28 (n = 286, 210)2.3 ± 13.522.3 ± 16.39
Change from Baseline to Endpoint (n = 365, 258)1.5 ± 13.862.9 ± 16.68
PrimaryChange From Baseline and Levels at Each Time Point for Serum Intact Parathyroid Hormone (iPTH)

Endpoint is Week 28 or the latest available measurement after baseline when Week 28 data is missing.

Time frame:
Every 4 weeks from baseline to Week 28
Reported as:
Mean · pg/mL
Change From Baseline and Levels at Each Time Point for Serum Intact Parathyroid Hormone (iPTH)
pg/mLPA21Sevelamer Carbonate
Change from Baseline to Week 4 (n = 365, 252)11.8 ± 177.3925.9 ± 186.42
Change from Baseline to Week 8 (n = 362, 258)8.6 ± 204.3940.8 ± 201.18
Change from Baseline to Week 12 (n = 352, 252)28.9 ± 315.8164.1 ± 204.11
Change from Baseline to Week 16 (n = 341, 241)54.5 ± 352.9252.3 ± 210.35
Change from Baseline to Week 20 (n = 334, 236)28.0 ± 233.1372.1 ± 228.03
Change from Baseline to Week 24 (n = 320, 226)27.7 ± 271.3179.6 ± 253.65
Change from Baseline to Week 28 (n = 310, 222)53.0 ± 287.1971.5 ± 278.03
Change from Baseline to Endpoint (n = 381, 260)52.3 ± 273.1467.5 ± 270.06

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PA21—78/391 (19.9%)208/391 (53.2%)
Sevelamer Carbonate—52/267 (19.5%)169/267 (63.3%)
Most frequent serious events
Showing 10 of 156
Most frequent serious events
EventPA21Sevelamer Carbonate
Fluid overloadMetabolism and nutrition disorders4/3916/267
PneumoniaInfections and infestations6/3916/267
AnaemiaBlood and lymphatic system disorders1/3913/267
Atrial fibrillationCardiac disorders1/3913/267
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders2/3913/267
HaematomaVascular disorders4/3910/267
Cardiac failure congestiveCardiac disorders3/3911/267
Cerebrovascular accidentNervous system disorders3/3910/267
Chest painGeneral disorders3/3911/267
CholelithiasisHepatobiliary disorders3/3910/267
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPA21Sevelamer Carbonate
HyperphosphataemiaMetabolism and nutrition disorders47/39129/267
HypertensionVascular disorders38/39120/267
Hyperparathyroidism secondaryEndocrine disorders15/39123/267
DiarrhoeaGastrointestinal disorders32/39115/267
HypotensionVascular disorders19/39121/267
Muscle spasmsMusculoskeletal and connective tissue disorders26/39116/267
HyperkalaemiaMetabolism and nutrition disorders17/39116/267
NauseaGastrointestinal disorders23/39111/267
HypophosphataemiaMetabolism and nutrition disorders22/39114/267
AnaemiaBlood and lymphatic system disorders15/39115/267

Baseline characteristics

For baseline characteristics, data from All Randomised patients was used.

Age, Continuous
Age, Continuous(years)PA21Sevelamer CarbonateTotal
Mean55.2 ± 13.2055.6 ± 14.5855.4 ± 13.77
Age, Categorical
Age, Categorical(Participants)PA21Sevelamer CarbonateTotal
<=18 years000
Between 18 and 65 years296190486
>=65 years9578173
Sex: Female, Male
Sex: Female, Male(Participants)PA21Sevelamer CarbonateTotal
Female171102273
Male220166386
Region of Enrollment
Region of Enrollment(participants)PA21Sevelamer CarbonateTotal
United States154133287
Europe8549134
Croatia16824
Russian Federation6544109
Serbia371855
Ukraine321547
South Africa213
08

Study locations

15 sites
  • San Antonio, Texas 78215, United States
  • Medizinische Abteilung Nephrologie und Dialyse
    St. Pölten, 3100, Austria
  • CHU Sart Tilman
    Liege, 4000, Belgium
  • Clinical Hospital Center Rijeka
    Rijeka, 51000, Croatia
  • Hospital with Polyclinic Novy Jicin
    Novy Jicin, 74101, Czech Republic
  • KfH Nierenzentrum Berlin-Neukoelln
    Berlin, 12045, Germany
  • Vidzemes Hospital
    Valmiera, LV-4201, Latvia
  • JSC "Diaverum Clinics"
    Klaipeda, LT-93220, Lithuania
  • Teaching Hospital no.1 of Medical University of Lodz
    Lodz, 90-153, Poland
  • Dialmed Clinic SRL
    Sibiu, 550135, Romania
  • Kemerovo Regional hospital
    Kemerovo, 650029, Russian Federation
  • Zvezdara Clinical Medical Center
    Belgrade, 11000, Serbia
  • St Augustines Hospital
    Durban, 4001, South Africa
  • Mykolayiv Regional Hospital
    Mykolayiv, 54058, Ukraine
  • Dorset County Hospital NHS Foundation Trust
    Dorset, DT1 2JY, United Kingdom
09

References and documents

Publications

  • Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, Rastogi A. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018 Oct;22(4):480-491. doi: 10.1111/hdi.12663. Epub 2018 Apr 15. PubMed 29656600 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Oct 2012 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 4 months after primary completion. A results delay was requested in Aug 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2011
First posted
Nov 3, 2011
Start
Sep 2011
Primary completionActual
Oct 2012
CompletionActual
Apr 2013
Results delay requested
Aug 8, 2013
Results first posted
Feb 17, 2014
Last update
Apr 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01464190
Lead sponsor
Vifor Pharma
Responsible party
Sponsor
First posted
Nov 3, 2011
Start date
Sep 2011
Primary completion
Oct 2012
Completion
Apr 2013
Results posted
Feb 17, 2014
Last update
Apr 1, 2014

Study contacts

Juergen Floege, MD
principal investigator · Medizinische Klinik II

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA21

Start the discussion